M Dumas1, F Nadal-Wollbold1, P Gaussem1, M Perez1, T Mirault1, R Létienne1, T Bourbon1, F Grelac1, B Le Grand1, C Bachelot-Loza1. 1. Inserm UMR S 765, Faculté de Pharmacie, Paris, FranceUniversité Paris Descartes, Sorbonne Paris Cité, Paris, FranceCentre de Recherche Pierre Fabre, 17, Avenue Jean Moulin, Castres cedex, FranceAP-HP, Hôpital Européen Georges Pompidou, Service d'Hématologie Biologique, Paris, France.
Abstract
BACKGROUND AND PURPOSE: New antithrombotic agents with the potential to prevent atherothrombotic complications are being developed to target receptors on platelets and other cells involved in plaque growth. The aim of this study was to investigate the antiplatelet effects of F 16618, a new non-peptidic PAR1 (thrombin receptor) antagonist. EXPERIMENTAL APPROACH: We investigated the inhibitory effect of F 16618 on human platelet aggregation ex vivo, in whole blood and washed platelets, by using a multiple-electrode platelet aggregometer based on impedance and an optical aggregometer, respectively. Its effects on whole-blood haemostasis (clot parameters) were analysed with the ROTEM thromboelastometry device and the platelet function analyser PFA-100. A guinea-pig model of arterial thrombosis was used to investigate its effects on thrombus formation in vivo. KEY RESULTS: F 16618 inhibited PAR1 agonist peptide (SFLLR-peptide)-induced washed platelet aggregation ex vivo. This effect was concentration-dependent and exhibited a competitive inhibition profile. Washed platelet aggregation, as well as P-selectin expression induced by thrombin, were significantly inhibited by 10 µM F 16618. In whole-blood experiments, 20 µM F 16618 inhibited SFLLR-induced platelet aggregation by 49%. In contrast, it had no effect on whole-blood haemostasis. In the guinea-pig model of carotid thrombosis, 0.32 mg·kg(-1) F 16618 doubled the occlusion time. CONCLUSIONS AND IMPLICATIONS: F 16618 was shown to have strong antithrombotic activity in vivo and moderate antiplatelet effects ex vivo. As these effects were not associated with major effects on physiological haemostasis, this molecule is a good antiplatelet drug candidate for use either alone or in combination with current treatments.
BACKGROUND AND PURPOSE: New antithrombotic agents with the potential to prevent atherothrombotic complications are being developed to target receptors on platelets and other cells involved in plaque growth. The aim of this study was to investigate the antiplatelet effects of F 16618, a new non-peptidic PAR1 (thrombin receptor) antagonist. EXPERIMENTAL APPROACH: We investigated the inhibitory effect of F 16618 on humanplatelet aggregation ex vivo, in whole blood and washed platelets, by using a multiple-electrode platelet aggregometer based on impedance and an optical aggregometer, respectively. Its effects on whole-blood haemostasis (clot parameters) were analysed with the ROTEM thromboelastometry device and the platelet function analyser PFA-100. A guinea-pig model of arterial thrombosis was used to investigate its effects on thrombus formation in vivo. KEY RESULTS:F 16618 inhibited PAR1 agonist peptide (SFLLR-peptide)-induced washed platelet aggregation ex vivo. This effect was concentration-dependent and exhibited a competitive inhibition profile. Washed platelet aggregation, as well as P-selectin expression induced by thrombin, were significantly inhibited by 10 µM F 16618. In whole-blood experiments, 20 µM F 16618 inhibited SFLLR-induced platelet aggregation by 49%. In contrast, it had no effect on whole-blood haemostasis. In the guinea-pig model of carotid thrombosis, 0.32 mg·kg(-1) F 16618 doubled the occlusion time. CONCLUSIONS AND IMPLICATIONS: F 16618 was shown to have strong antithrombotic activity in vivo and moderate antiplatelet effects ex vivo. As these effects were not associated with major effects on physiological haemostasis, this molecule is a good antiplatelet drug candidate for use either alone or in combination with current treatments.
Authors: P Andrade-Gordon; C K Derian; B E Maryanoff; H C Zhang; M F Addo; B P Damiano; M R D'Andrea; A L Darrow; L de Garavilla; A J Eckardt; E C Giardino; B J Haertlein; D F McComsey Journal: J Pharmacol Exp Ther Date: 2001-07 Impact factor: 4.030
Authors: Claudia K Derian; Bruce P Damiano; Michael F Addo; Andrew L Darrow; Michael R D'Andrea; Mark Nedelman; Han-Cheng Zhang; Bruce E Maryanoff; Patricia Andrade-Gordon Journal: J Pharmacol Exp Ther Date: 2003-02 Impact factor: 4.030
Authors: Elisa Rossi; Miguel Pericacho; Christilla Bachelot-Loza; Dominique Pidard; Pascale Gaussem; Sonia Poirault-Chassac; Francisco J Blanco; Carmen Langa; Consuelo González-Manchón; Jose M Lopez Novoa; David M Smadja; Carmelo Bernabeu Journal: Cell Mol Life Sci Date: 2017-10-28 Impact factor: 9.261
Authors: Ivan D Tarandovskiy; Hye Kyung H Shin; Jin Hyen Baek; Elena Karnaukhova; Paul W Buehler Journal: Sci Rep Date: 2020-03-03 Impact factor: 4.379